2 results
Approved WMOCompleted
Primary objective:To demonstrate the efficacy of Rifaximin -EIR 400 mg Tablet (800mg /BID, total daily dose 1600 mg) versus placebo in the prevention of endoscopic Crohn*s disease recurrence following ileocolonic resection
Approved WMORecruiting
This study is being carried out to investigate the treatment with benralizumab in patients with active HES.The purpose of this study is to see if benralizumab, given as injections under the skin, can help control your HES better if it is added to…